TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $50.45, but opened at $51.61. TransMedics Group shares last traded at $49.81, with a volume of 1,249 shares changing hands.
Wall Street Analysts Forecast Growth
TMDX has been the subject of several research reports. Morgan Stanley raised their price objective on shares of TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 3rd. Oppenheimer raised their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. Cowen increased their price objective on TransMedics Group from $45.00 to $50.00 in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $26.00 to $48.00 in a report on Tuesday, August 2nd. Finally, Cowen raised their target price on shares of TransMedics Group from $39.00 to $45.00 and gave the company an "outperform" rating in a research note on Tuesday, July 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.00.
Get
TransMedics Group alerts:
TransMedics Group Stock Down 1.8 %
The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $44.98 and a 200-day simple moving average of $32.77.
TransMedics Group (NASDAQ:TMDX – Get Rating) last released its earnings results on Monday, August 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative net
margin of 92.76% and a negative return on equity of 74.20%. The company had revenue of $20.52 million during the quarter, compared to analyst estimates of $16.26 million. During the same period in the prior year, the firm posted ($0.39) EPS. On average, research analysts predict that TransMedics Group, Inc. will post -1.57 EPS for the current fiscal year.
Insider Activity at TransMedics Group
In other TransMedics Group news, CEO Waleed H. Hassanein sold 2,277 shares of the company's stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $55.00, for a total transaction of $125,235.00. Following the sale, the chief executive officer now directly owns 464,008 shares of the company's stock, valued at $25,520,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, VP John F. Carey sold 1,500 shares of the firm's stock in a transaction on Monday, July 11th. The stock was sold at an average price of $32.98, for a total transaction of $49,470.00. Following the completion of the sale, the vice president now owns 379 shares of the company's stock, valued at approximately $12,499.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 2,277 shares of the company's stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $55.00, for a total transaction of $125,235.00. Following the completion of the transaction, the chief executive officer now owns 464,008 shares in the company, valued at $25,520,440. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,905 shares of company stock valued at $7,240,928. 8.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in TransMedics Group during the second quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in TransMedics Group in the 2nd quarter valued at $69,000. Amalgamated Bank acquired a new position in TransMedics Group in the 1st quarter valued at $114,000. Ensign Peak Advisors Inc bought a new position in TransMedics Group during the 4th quarter worth $97,000. Finally, Captrust Financial Advisors lifted its holdings in shares of TransMedics Group by 738.8% during the first quarter. Captrust Financial Advisors now owns 5,788 shares of the company's stock worth $156,000 after buying an additional 5,098 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company's stock.
TransMedics Group Company Profile
(Get Rating)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
